Physician profile
Cherry E Nelson
NPI 1003305525
$5,640.74
in general payments reported to CMS, 2019-2025
10 companies · $1,552 in 2025
The $1,552 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,134 · 2022: $669 · 2023: $919 · 2024: $1,366 · 2025: $1,552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,837.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,532.14 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $581.24 | 2021-2025 | Wegovy |
| Pfizer INC. | $557.26 | 2023-2025 | |
| Abbvie INC. | $438.32 | 2021-2025 | |
| Glaxosmithkline, LLC. | $387.49 | 2023-2024 | Arexvy, Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $371.60 | 2024-2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $371.09 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $370.25 | 2022 | |
| Organon LLC | $17.46 | 2024 | |
| Lilly USA, LLC | $13.89 | 2024 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cherry Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.